dr. luke on the fda approval of adjuvant nivolumab in melanoma
Published 6 years ago • 163 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
1:10
dr. luke on adjuvant therapies in development for melanoma
-
5:00
fda d.i.s.c.o.: nivolumab for adjuvant treatment of patients with melanoma
-
0:59
dr. weber on the fda approval for fixed-dose of nivolumab
-
1:45
dr. luke on impactful data in the field of melanoma
-
1:06
dr. luke on the future role of immunotherapy combinations in melanoma
-
1:30
dr. jason luke discusses nivolumab and pembrolizumab in melanoma
-
1:01
dr. luke on the future of combination therapy in melanoma
-
1:57
dr. luke discusses the controversy surrounding ipilimumab/nivolumab combo in melanoma
-
1:36:36
navigating a uveal melanoma diagnosis
-
59:06
e 38: small choroidal melanomas: advances in laser with dr. tim murray
-
59:28
ocular melanoma: innovative treatments and beyond
-
1:15
dr. weber on nivolumab in the adjuvant setting for melanoma
-
1:10
dr. luke on ongoing studies with immunotherapy in melanoma
-
0:43
dr. eng on the fda approval of nivolumab plus ipilimumab in crc
-
1:51
dr. luke on immunotherapy diagnostics in melanoma
-
1:34
fda approves frontline nivolumab for advanced melanoma
-
2:05
dr. luke on challenges with immunotherapy in melanoma
-
25:50
melanoma | 2022 oneoncology conference
-
1:11
dr. weber on the fda approval of adjuvant dabrafenib/trametinib in braf-mutant melanoma
-
1:20
dr. luke on immunotherapy advancements in melanoma
-
1:08
fda approval of adjuvant dabrafenib/trametinib in braf melanoma
-
0:59
dr. luke on treatment options in metastatic melanoma